# MELODY trial (nirsevimab in healthy late-preterm and term infants)

Study · id `maternal:melody-trial` · Maternal & Newborn Atlas · release `fc5a600ec7387e71` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: MELODY

Browse, life stage: Newborn; Infant follow-up  
Browse, care area: The baby's first year  

## In plain language

A large international trial in which healthy babies born at 35 weeks or later received one injection of the RSV antibody nirsevimab or a placebo before an RSV season. The antibody lowered RSV lung infections that needed medical attention. For hospital admission for RSV, the secondary outcome, the result was less clear (P = 0.07).

## Technical summary

Registry NCT03979313 (MELODY), lead sponsor AstraZeneca (industry), phase 3, interventional, randomised, parallel, quadruple masking, prevention; COMPLETED. Registry enrolment is 3012 (actual); the registry's participant flow lists all subjects as 1003 placebo and 2009 nirsevimab infants, and the Primary Cohort as 496 placebo and 994 nirsevimab, which are the 1490 infants randomised in the paper's abstract; each count is recorded with its own basis. Results first posted on the registry on 2024-02-28. The paper (2022) was read as a PubMed abstract only. The registry lists 31 countries across Europe, the Americas, Asia, Africa and Oceania.

## Key facts

- Design: Phase 3, randomised, double-blind, placebo-controlled trial in infants. Registry values: allocation randomized, intervention model parallel, masking quadruple, primary purpose prevention. Infants born at a gestational age of at least 35 weeks were randomised 2:1 to a single intramuscular injection of nirsevimab or placebo before the start of an RSV season (PubMed abstract).
- Phase: Phase 3
- Enrolled: 3012 infants, all subjects (participant flow: 1003 placebo and 2009 nirsevimab; ClinicalTrials.gov gives no unit in the count field) (enrolled count; A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY), snapshot `maternal:ctgov-nct03979313-2026-10-15`, retrieved 2026-10-15); 1490 infants in the primary cohort (paper abstract; participant flow: 496 placebo and 994 nirsevimab) (randomized count; Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants, snapshot `maternal:pubmed-35235726-2026-10-15`, retrieved 2026-10-15)
- Started: 2019-07-23 (actual) (A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY), snapshot `maternal:ctgov-nct03979313-2026-10-15`, retrieved 2026-10-15)
- Primary completion: 2021-03-11 (actual) (A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY), snapshot `maternal:ctgov-nct03979313-2026-10-15`, retrieved 2026-10-15)
- Completion: 2023-03-21 (actual) (A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY), snapshot `maternal:ctgov-nct03979313-2026-10-15`, retrieved 2026-10-15)
- Results first posted: 2024-02-28 (actual) (A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY), snapshot `maternal:ctgov-nct03979313-2026-10-15`, retrieved 2026-10-15)
- Countries: United States; Argentina; Australia; Austria; Belgium; Bulgaria; Canada; Chile; Colombia; Czechia; Estonia; Finland; France; Germany; Israel; Italy; Japan; Latvia; Lithuania; Mexico; New Zealand; Panama; Poland; Russia; South Africa; South Korea; Spain; Sweden; Türkiye; Ukraine; United Kingdom (A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY), snapshot `maternal:ctgov-nct03979313-2026-10-15`, retrieved 2026-10-15)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), snapshot `maternal:ctgov-nct03979313-2026-10-15`, retrieved 2026-10-15)

## Connected pages

- Tests a single dose of nirsevimab in infants: Nirsevimab (`maternal:nirsevimab`)

## Provenance

Content hash: b14d8cfc9698babcde1828a79ead35455a994e76fc04c2403ee2b936523b3d23
Last substantive edit: 2026-10-15
Evidence last checked: 2026-10-15